

November 5, 2015



## **OPKO to Announce Third Quarter Operating and Financial Results on November 9, 2015**

MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK), a multinational biopharmaceutical and diagnostics company, will release operating and financial results for the three months ended September 30, 2015, after the close of the U.S. financial markets on Monday, November 9, 2015.

OPKO's senior management will provide a business update and discuss its results in greater detail in a conference call and live audio webcast at 4:30 p.m. Eastern time on Monday, November 9, 2015.

The conference call dial-in information is listed below. To access the webcast, please log on to the OPKO website at [www.opko.com](http://www.opko.com) at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

### **CONFERENCE CALL & WEBCAST INFORMATION**

WHEN: Monday, November 9, 2015, 4:30 p.m. ET  
DOMESTIC DIAL-IN: (866) 634-2258  
INTERNATIONAL DIAL-IN: (330) 863-3454  
PASSCODE: 66021053

For those unable to participate in the conference call or webcast, a replay will be available beginning November 9, 2015 at 7:30 p.m. ET until November 15, 2015 at 11:59 p.m. ET. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 66021053.

The replay can also be accessed for a period of time on OPKO's website at [www.opko.com](http://www.opko.com).

### **About OPKO Health, Inc.**

OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros®1 in-office immunoassay platform. Our pharmaceutical business features Rayaldee™, a treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (March 29, 2016 PDUFA date) and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation approved by FDA and pending launch by partner Tesaro, IV formulation in Phase 3). Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia (entering Phase

2a). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at [www.opko.com](http://www.opko.com).

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20151105006539/en/>

OPKO Health, Inc.

Tara Mackay, 305-575-4100

Investor Relations

or

**Media**

Rooney & Associates

Terry Rooney, 212-223-0689

[trooney@rooneyco.com](mailto:trooney@rooneyco.com)

or

Marion Janic, 212-223-4017

[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)

or

**Investors**

LHA

Anne Marie Fields, 212-838-3777

[afields@lhai.com](mailto:afields@lhai.com)

or

Bruce Voss, 310-691-7100

[bvoss@lhai.com](mailto:bvoss@lhai.com)

Source: OPKO Health, Inc.